PAKOLA STEVE 4

What Happened

• Steve Pakola, Chief Medical Officer of REGENXBIO (RGNX), exercised options to acquire 2,161 shares at $7.86 per share (total cost $16,985) on July 2, 2026, and the same 2,161 shares were sold in the open market that day at $13.64 per share for total proceeds of $29,476.
• The filing also includes a related derivative conversion/disposition line for 2,161 shares recorded at $0.00 (reported as a derivative transaction).

Key Details

• Transaction date: July 2, 2026.
• Exercise (code M): 2,161 shares acquired at $7.86 each — total cash paid $16,985.
• Sale (code S): 2,161 shares sold at $13.64 each — total proceeds $29,476.
• Derivative disposition entry: 2,161 shares at $0.00 (reported separately in the Form 4).
• Sale executed pursuant to a Rule 10b5-1 trading plan (footnote F1).
• Option grant background (footnote F2): the option covers 103,698 shares; 25% vested on Jan 2, 2026, with the remainder vesting monthly over the next 36 months.
• Shares owned after the transaction: not specified in the Form 4 filing.
• Filing date: July 6, 2026 (no late-filing flag noted in the summary information provided).

Context

• This pattern — exercising vested options and immediately selling the resulting shares — is a common way for insiders to monetize option value (often called a cashless exercise or sell-to-cover). The presence of a 10b5-1 plan indicates the sale was made under a pre-arranged trading program, which is intended to avoid questions about timing.
• The economic result here: Pakola paid $16,985 to exercise and received $29,476 from the sale, implying gross proceeds exceeding exercise cost (pre-tax difference ≈ $12,491). This is factual reporting of the transactions, not a commentary on future company prospects.